On the morning of March 12, the Hong Kong Stock Connect Innovative Drug ETF (520880) showed steady performance during the trading session, with its on-market price currently up 1.23%. The fund's latest size is 2.312 billion yuan, making it the largest ETF tracking the same underlying index.
Among the constituent stocks, Biocytogen-B, PegBio Co-B, and Connock Murray-B were the top performers, with gains of 4.69%, 3.84%, and 2.95% respectively. Conversely, several stocks including Zhonghui Biology-B, Haixi New Drug, and Changfeng Pharmaceutical fell more than 3%.
On the news front, the 2026 Government Work Report for the first time explicitly identified biopharmaceuticals as a national "emerging pillar industry," elevating its strategic positioning. The report also mentioned the introduction of a commercial health insurance innovative drug catalog, which is expected to provide long-term policy and payment support for the sector. Concurrently, at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, the R&D progress of Chinese innovative drug companies garnered global attention, indicating continued vibrancy in industry前沿 dynamics.
Recently, business development transactions in China's innovative drug sector have been active, with impressive deal values and a shift towards earlier R&D stages, highlighting the sustained global recognition of their cost and efficiency advantages.
Debon Securities pointed out that innovative drugs have been included in the Government Work Report for three consecutive years, with the 2026 report explicitly upgrading the pharmaceutical and biological industry from an emerging industry to a pillar industry. Domestic innovative drugs are receiving policy emphasis, and the industry continues to make breakthroughs.
The Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index. The top ten weighted constituents of this index are Sino Biopharmaceutical Limited, BeiGene, Ltd., Innovent Biologics, Inc., Akeso, Inc., China Biologic Products Holdings, Inc., Hansoh Pharmaceutical Group Company Limited, 3SBio Inc., Kelun-Biotech Biopharmaceutical Co., Ltd., China Medical System Holdings Limited, and Zai Lab Limited. Its feeder funds (Feeder A: 025220, Feeder C: 025221) also track this index.
Data is sourced from the Shanghai and Shenzhen Stock Exchanges and public information.
Note: This ETF does not charge a sales service fee. When investors subscribe for or redeem fund shares, the subscription/redemption agent may charge a commission of up to 0.5%, which includes relevant fees charged by the stock exchange and registration机构. The subscription fee for Hong Kong Stock Connect Innovative Drug ETF Feeder A is 1% for amounts below 1 million yuan, 0.6% for amounts between 1 million yuan (inclusive) and 2 million yuan, and 1,000 yuan per transaction for amounts of 2 million yuan (inclusive) and above. The redemption fee is 1.5% for holdings less than 7 days and 0% for holdings of 7 days (inclusive) or more; no sales service fee is charged. Hong Kong Stock Connect Innovative Drug ETF Feeder C charges no subscription fee; the redemption fee is 1.5% for holdings less than 7 days and 0% for holdings of 7 days (inclusive) or more; the sales service fee is 0.2%.
Risk Disclosure: The above products are issued and managed by the fund manager. Selling agencies do not assume responsibility for the investment, repayment, and risk management of the products. Investors should carefully read the "Fund Contract," "Prospectus," "Fund Product Summary," and other fund legal documents to understand the risk-return characteristics of the fund and choose products that match their own risk tolerance. Past performance of the fund is not indicative of its future results. Fund investment carries risks! Selling institutions (including the fund manager's direct sales机构 and other selling机构) assess the risk of this fund based on relevant laws and regulations. Investors should promptly pay attention to the appropriateness opinions issued by the fund manager. The appropriateness opinions from various selling institutions may not necessarily be consistent, and the risk等级 evaluation results of the fund product provided by fund selling institutions shall not be lower than the risk等级 evaluation result made by the fund manager. There are differences between the fund's risk-return characteristics as described in the fund contract and the fund's risk等级 due to different consideration factors. Investors should understand the risk-return profile of the fund and carefully select fund products based on their own investment objectives, horizon, experience, and risk tolerance, and bear the risks themselves. The registration of the above funds by the China Securities Regulatory Commission does not indicate a substantive judgment or guarantee of their investment value, market prospects, or returns. Fund investment carries risks.
A MACD golden cross signal has formed, and these stocks are performing well.
Comments